Newton001-Developing a partnership to inform UK-Brazil TB control:Investigating BCG vaccination efficacy following latent TB treatment (TBTVacc)

结核病是全球疾病负担的一个主要原因。我们计划调查在个体完成潜伏性结核病治疗后，卡介苗接种对结核病的免疫是否有所不同。这将使我们能够测试卡介苗是否可以在清除结核菌后保护个体。我们将在英国和巴西研究人员之间建立伙伴关系，开展以下工作：审查和总结所有已发表的关于卡介苗评估潜伏性结核病治疗后保护作用的研究。我们将利用这些信息和专家意见，试图量化结核病治疗后接种疫苗的影响。我们将组织两个研讨会，一个在巴西，一个在英国，以加强合作伙伴之间现有的合作。我们将利用这些研讨会来发展我们的试点研究，并为一项重大试验计划拨款申请。我们将确保在英国为巴西学生提供培训机会，在巴西为英国学生提供培训机会。我们将在巴西进行一项试点研究，以调查进行为期6个月的试验的可行性。这项初步研究将检查40人在完成潜伏性结核病治疗后立即接种卡介苗后的免疫学变化。

Tuberculosis (TB) is a major cause of the global disease burden. We plan to investigate whether the human immunity to tuberculosis as a result of BCG vaccination is different after individuals complete treatment for latent TB. This will allow us to test whether BCG can protect individuals following clearance of the tuberculosis bacterium. We would develop a partnership between UK and Brazilian researchers to undertake the following: Review and summarise any published studies of BCG assessing protection after treatment for latent TB. We will use this information and expert views to try and quantify the impact of vaccinating people after TB treatment.We would organise two workshops, one in Brazil and one in the UK that strengthen the existing collaboration between partners. We will use these workshops to develop our pilot study and to plan the grant application for a major trial. We would ensure there are training opportunities in the UK for Brazilian students, and UK students in Brazil.We will undertake a pilot study in Brazil to investigate the feasibility of undertaking a trial over a 6 month period. The pilot study would examine immunological changes after BCG vaccination in 40 people immediately following the completion of treatment for latent TB.